LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 9 of 15: Cell count and normalized growth rate inhibition values within biological replicate 2. - Dataset (ID:20246)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Normalized Growth Rate Inhibition Value |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Hs 578T | PI103 | 10 | uM | LJP6 | 2 | I13 | 72 | hr | 765 | 680 | 3095 | 0.2197 | -0.0568 |
Hs 578T | PI103 | 10 | uM | LJP6 | 3 | I13 | 72 | hr | 765 | 693 | 3066 | 0.2260 | -0.0482 |
Hs 578T | Dovitinib | 0.04 | uM | LJP5 | 1 | E24 | 72 | hr | 765 | 2540 | 3140 | 0.8088 | 0.8022 |
Hs 578T | Dovitinib | 0.04 | uM | LJP5 | 2 | E24 | 72 | hr | 765 | 2499 | 3151 | 0.7929 | 0.7852 |
Hs 578T | Dovitinib | 0.04 | uM | LJP5 | 3 | E24 | 72 | hr | 765 | 2396 | 3152 | 0.7601 | 0.7486 |
Hs 578T | Dovitinib | 0.12 | uM | LJP5 | 1 | E23 | 72 | hr | 765 | 1932 | 3140 | 0.6152 | 0.5757 |
Hs 578T | Dovitinib | 0.12 | uM | LJP5 | 2 | E23 | 72 | hr | 765 | 1914 | 3151 | 0.6073 | 0.5667 |
Hs 578T | Dovitinib | 0.12 | uM | LJP5 | 3 | E23 | 72 | hr | 765 | 1723 | 3152 | 0.5466 | 0.4880 |
Hs 578T | Dovitinib | 0.37 | uM | LJP5 | 1 | E22 | 72 | hr | 765 | 1305 | 3140 | 0.4156 | 0.2997 |
Hs 578T | Dovitinib | 0.37 | uM | LJP5 | 2 | E22 | 72 | hr | 765 | 1270 | 3151 | 0.4030 | 0.2817 |
Hs 578T | Dovitinib | 0.37 | uM | LJP5 | 3 | E22 | 72 | hr | 765 | 1300 | 3152 | 0.4124 | 0.2963 |
Hs 578T | Dovitinib | 1.11 | uM | LJP5 | 1 | E21 | 72 | hr | 765 | 1257 | 3140 | 0.4003 | 0.2760 |
Hs 578T | Dovitinib | 1.11 | uM | LJP5 | 2 | E21 | 72 | hr | 765 | 1134 | 3151 | 0.3598 | 0.2125 |
Hs 578T | Dovitinib | 1.11 | uM | LJP5 | 3 | E21 | 72 | hr | 765 | 1198 | 3152 | 0.3800 | 0.2455 |
Hs 578T | Dovitinib | 3.33 | uM | LJP5 | 1 | E20 | 72 | hr | 765 | 1135 | 3140 | 0.3614 | 0.2136 |
Hs 578T | Dovitinib | 3.33 | uM | LJP5 | 2 | E20 | 72 | hr | 765 | 1221 | 3151 | 0.3874 | 0.2572 |
Hs 578T | Dovitinib | 3.33 | uM | LJP5 | 3 | E20 | 72 | hr | 765 | 1064 | 3152 | 0.3375 | 0.1752 |
Hs 578T | Dovitinib | 10 | uM | LJP5 | 1 | E19 | 72 | hr | 765 | 1144 | 3140 | 0.3643 | 0.2183 |
Hs 578T | Dovitinib | 10 | uM | LJP5 | 2 | E19 | 72 | hr | 765 | 1061 | 3151 | 0.3367 | 0.1736 |
Hs 578T | Dovitinib | 10 | uM | LJP5 | 3 | E19 | 72 | hr | 765 | 1268 | 3152 | 0.4022 | 0.2806 |
Hs 578T | GSK 690693 | 0.04 | uM | LJP5 | 1 | F24 | 72 | hr | 765 | 2581 | 3140 | 0.8219 | 0.8164 |
Hs 578T | GSK 690693 | 0.04 | uM | LJP5 | 2 | F24 | 72 | hr | 765 | 2752 | 3151 | 0.8732 | 0.8715 |
Hs 578T | GSK 690693 | 0.04 | uM | LJP5 | 3 | F24 | 72 | hr | 765 | 2828 | 3152 | 0.8971 | 0.8965 |
Hs 578T | GSK 690693 | 0.12 | uM | LJP5 | 1 | F23 | 72 | hr | 765 | 2448 | 3140 | 0.7795 | 0.7699 |
Hs 578T | GSK 690693 | 0.12 | uM | LJP5 | 2 | F23 | 72 | hr | 765 | 2469 | 3151 | 0.7834 | 0.7747 |